source
- Sanofi scraps most atopic dermatitis trials after amlitelimab fails to outperform standard careSanofi announced it is halting all but one ongoing trial for amlitelimab, an OX40‑ligand antibody acquired through its $1.4 billion purchase of Kymab. The decision follows the Phase 3 COAST‑1 stud…
- Scribe Therapeutics raises $129 million in rare early-stage IPO to fund epigenetic heart disease therapyScribe Therapeutics, founded by Jennifer Doudna, completed an IPO raising nearly $129 million, selling 8.58 million shares at $15 each. It is the first gene‑editing company to go public in more tha…